1-dimethylamino-pyridinium | 67266-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-dimethylamino-pyridinium
• 英文别名: N-Dimethylaminopyridinium；N,N-dimethylpyridin-1-ium-1-amine
• CAS: 67266-39-1
• 化学式: C₇H₁₁N₂
• 分子量: 123.178
• InChiKey: CNLIZIJWOMRBLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  7.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• 2-AMINOQUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20090227570A1

  公开（公告）日：2009-09-10

  The present invention is concerned with 2-aminoquinoline derivatives of formula I where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, and n are as defined in the specification and claims, their use 5-HT 5A receptor antagonists, their manufacture, and pharmaceutical compositions containing them.

  本发明涉及式I的2-氨基喹啉衍生物，其中R1、R2、R3、R4、R5、R6、A和n如规范和声明中定义，它们用作5-HT5A受体拮抗剂，它们的制造以及含有它们的药物组合物。
• [EN] DISUBSTITUTED 3-PYRAZOLE CARBOXYLATES AND A PROCESS FOR THEIR PREPARATION VIA ACYLATION OF ENOLATES<br/>[FR] 3-PYRAZOLE CARBOXYLATES DISUBSTITUÉS ET LEUR PROCÉDÉ DE PRÉPARATION PAR ACYLATION D'ÉNOLATES
  申请人：BAYER AG

  公开号：WO2019243178A1

  公开（公告）日：2019-12-26

  The present invention relates to disubstituted 3-pyrazole carboxylates of the formula (I) and a process for their preparation (I) wherein R1, R2, R3, R4 and n are defined as above.

  本发明涉及公式（I）的二取代3-吡唑羧酸酯以及其制备方法（I）其中R1、R2、R3、R4和n如上所定义。
• SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP
  申请人：KARKI Rajeshri Ganesh

  公开号：US20120122764A1

  公开（公告）日：2012-05-17

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.

  本发明提供了一种具有化学式I的化合物； 或其药学上可接受的盐，其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，B，X，m和n在此处被定义。该发明还涉及制造该发明化合物的方法及其治疗用途。本发明进一步提供了该发明化合物的药物组合物，以及具有药理活性剂和该发明化合物的组合。
• [EN] CRYSTALLINE FORMS OF SELETALISIB<br/>[FR] FORMES CRISTALLINES DE SÉLÉTALISIB
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2018219772A1

  公开（公告）日：2018-12-06

  Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human ΡΒΚδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  晶态形式的塞来替利西布，被指定为B型和F型，并在此处进行表征，作为选择性PI3激酶酶抑制剂，特别是人类ΡΒΚδ亚型，因此在医学上具有益处，例如在治疗炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病方面。
• METHODS FOR PRODUCING PERFLUOROALKANEDI(SULFONYL CHLORIDE)
  申请人：UMEMOTO TERUO

  公开号：US20090105502A1

  公开（公告）日：2009-04-23

  Novel methods for preparing perfluoroalkanedi(sulfonyl chloride) are disclosed as are uses for these compounds. In one aspect, a method comprising reacting dibromoperfluoroalkane with Na 2 S 2 O 4 followed by treating with chlorine, an organic compound, and then chlorine to form perfluoroalkanedi(sulfonyl chloride) is provided. Novel perfluoroalkanedi(sulfonyl bromide) compounds are also disclosed.

  揭示了制备全氟烷二(磺酰氯)的新方法，以及这些化合物的用途。在一个方面，提供了一种方法，包括将二溴全氟烷与Na2S2O4反应，然后用氯、有机化合物和氯处理，形成全氟烷二(磺酰氯)。还披露了新型全氟烷二(磺酰溴)化合物。